Cell & Gene Therapy Update with Joe DePinto, InspiroGene by McKesson | TWIRx
From Pharmacy Podcast Network · · 36 min
This plays from the publisher's own server. We do not host a copy.
Description
Cell and gene therapy has entered a new phase. The science is advancing rapidly, but the harder question is increasingly becoming: How do we actually get these therapies to the right patient, at the right treatment center, with the financing, logistics, clinical support, and follow-up required?
That is the problem McKesson is trying to address through InspiroGene, its dedicated cell-and-gene commercialization business. McKesson built InspiroGene to connect manufacturers, payers, providers, treatment centers and patients across the CGT journey. McKesson (https://www.mckesson.com/about-us/newsroom/press-releases/2024/mckesson-launches-inspirogene-a-dedicated-business-to-guide-and-support-the-commercialization-of-cell-and-gene-therapies/?utm_source=chatgpt.com)
1. McKesson: Building the infrastructure around the therapy
A major area of focus for Joe and McKesson is what happens after a therapy proves clinically viable.
In 2026, Joe DePinto and Biologics by McKesson outlined the need for patient hubs purpose-built specifically for cell and gene therapies. These are more complex than conventional specialty-drug hubs because CGT may involve eligibility screening, treatment-center coordination, benefit investigation, financial assistance, scheduling, logistics, long-term follow-up and caregiver support. McKesson Biologics (https://biologics.mckesson.com/news/?utm_source=chatgpt.com)
McKesson has also developed an interactive map covering qualified treatment centers across 109 U.S. metropolitan regions, addressing another fundamental problem: patients may need to travel significant distances to receive CGT. McKesson (https://www.mckesson.com/business-solutions/our-businesses/inspirogene-by-mckesson/?utm_source=chatgpt.com)
Question for Joe:
“Joe, the scientific breakthrough gets most of the headlines, but is the bigger challenge now building the infrastructure that allows a patient to actually receive the therapy?”
Follow-up:
“Where do you currently see the biggest friction — reimbursement, treatment-center capacity, logistics, patient identification, or ongoing follow-up?”
2. FDA is actively trying to speed cell and gene therapy development
FDA has made a noticeable regulatory shift in 2026.
In June, FDA issued draft guidance allowing gene-therapy developers to rely more heavily on existing platform knowledge and prior scientific information, potentially reducing redundant testing for products using similar genome-editing technologies. FDA has also issued guidance providing more flexibility around chemistry, manufacturing and controls for CGT products. U.S. Food and Drug Administration (https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-help-accelerate-cell-and-gene-therapies-patients?utm_source=chatgpt.com)
FDA says it has now approved close to 50 cell and gene therapies, signaling that CGT is moving well beyond a small experimental category. U.S. Food and Drug Administration (https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation?utm_source=chatgpt.com)
TWIRx takeaway:
The regulatory conversation is shifting from “Can we safely approve these therapies?” toward “How do we safely accelerate an entire therapeutic platform?”